Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

80
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
80
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

109
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
109
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

178
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
178
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

111
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
111
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

280
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
280
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

122
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
122

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethical Considerations for Heart Organ Allocation: Current Landscape and Future Policy Guidance: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry.

JAMA·2026
Same author

Obituary to Prof. Herbert J. Meiselman.

Clinical hemorheology and microcirculation·2025
Same author

Application of Telemedicine in the Management of Cardiovascular Diseases: A Focus on Heart Failure.

Reviews in cardiovascular medicine·2025
Same author

JCF in Case You Missed It! AAHFN 2025 Annual Meeting.

Journal of cardiac failure·2025
Same author

Prevalence and Cardiopulmonary Characteristics of Post-COVID Syndrome at a Hungarian Tertiary Referral Hospital.

Journal of clinical medicine·2025

Related Experiment Video

Updated: Nov 25, 2025

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
12:24

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse

Published on: June 20, 2014

10.2K

Update on COVID-19 Myocarditis.

Arianne Clare C Agdamag1, Jonathan B Edmiston2, Victoria Charpentier2

  • 1Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.

Medicina (Kaunas, Lithuania)
|December 15, 2020
PubMed
Summary
This summary is machine-generated.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus causing Coronavirus Disease 2019 (COVID-19), can lead to serious cardiac complications. Early recognition and intervention are crucial for managing these cardiovascular manifestations and improving patient outcomes.

Keywords:
COVID-19cardiogenic shockcoronavirusheart failuremyocarditis

More Related Videos

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

7.9K
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.5K

Related Experiment Videos

Last Updated: Nov 25, 2025

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
12:24

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse

Published on: June 20, 2014

10.2K
Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

7.9K
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.5K

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Virology

Background:

  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) primarily causes respiratory illness but also affects multiple organ systems.
  • Cardiac manifestations of COVID-19 are increasingly recognized, including myocarditis, arrhythmias, heart failure, and cardiogenic shock.
  • Myocarditis in COVID-19 may stem from direct viral damage or an overactive immune response.

Purpose of the Study:

  • To review the cardiac manifestations associated with SARS-CoV-2 infection.
  • To discuss diagnostic approaches for COVID-19-related cardiac complications.
  • To outline current and potential management strategies for these cardiovascular issues.

Main Methods:

  • Diagnosis relies on patient history, clinical examination, laboratory tests, and non-invasive imaging.
  • Cardiac MRI is the preferred imaging modality when available.
  • Endomyocardial biopsy may be used for uncertain diagnoses.

Main Results:

  • COVID-19 can lead to various cardiac complications, including myocarditis and heart failure.
  • Management is primarily supportive, with potential use of antiviral medications, steroids, and convalescent plasma for severe cases.
  • Advanced mechanical circulatory support may be necessary for refractory cardiogenic shock or arrhythmias.

Conclusions:

  • Early identification and aggressive management of cardiac complications in COVID-19 are vital for reducing morbidity and mortality.
  • The understanding and treatment strategies for COVID-19-associated cardiac issues are expected to evolve.
  • Prompt intervention can significantly impact patient outcomes in cases of severe cardiac involvement.